AbbVie Inc (ABBV)vsEquinor ASA ADR (EQNR)
ABBV
AbbVie Inc
$207.86
+2.51%
HEALTHCARE · Cap: $358.55B
EQNR
Equinor ASA ADR
$36.69
-0.60%
ENERGY · Cap: $91.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Equinor ASA ADR generates 66% more annual revenue ($104.26B vs $62.82B). ABBV leads profitability with a 5.8% profit margin vs 5.3%. ABBV appears more attractively valued with a PEG of 0.57. EQNR earns a higher WallStSmart Score of 65/100 (B-).
ABBV
Buy63
out of 100
Grade: C+
EQNR
Strong Buy65
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-19.7%
Fair Value
$168.33
Current Price
$207.86
$39.53 premium
Margin of Safety
+46.5%
Fair Value
$53.41
Current Price
$36.69
$16.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 31.6%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Strong operational efficiency at 31.5%
Large-cap with strong market position
Growing faster than its price suggests
Attractively priced relative to earnings
Earnings expanding 29.2% YoY
Generating 2.1B in free cash flow
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.8%
Distress zone — elevated risk
5.3% margin — thin
Weak financial health signals
Revenue declined 5.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.
Bull Case : EQNR
The strongest argument for EQNR centers on Operating Margin, Market Cap, PEG Ratio. PEG of 0.93 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 98.9x leaves little room for execution misses.
Bear Case : EQNR
The primary concerns for EQNR are Profit Margin, Piotroski F-Score, Revenue Growth.
Key Dynamics to Monitor
ABBV carries more volatility with a beta of 0.30 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
EQNR scores higher overall (65/100 vs 63/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Equinor ASA ADR
ENERGY · OIL & GAS INTEGRATED · USA
Equinor ASA, an energy company, is engaged in the exploration, production, transportation, refining and marketing of petroleum and petroleum products and other forms of energy, as well as other companies in Norway and internationally. The company is headquartered in Stavanger, Norway.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?